GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented by Dr. Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology at the Emory University School of Medicine in Atlanta. Dr. Newman is an International Principal Investigator and Site Principal Investigator of the REVERSE trial. Widely recognized as one of the leading authorities on Leber Hereditary Optic Neuropathy (LHON), Dr. Newman has been integral to defining and describing LHON pathophysiology and clinical declarations.
North American Neuro-Ophthalmology Society (NANOS)
March 16-21, 2019 – Las Vegas (NV, USA)
“rAAV2/2-ND4 Treatment of Leber Hereditary Optic Neuropathy: 72-Week Data from the REVERSE Phase III Clinical Trial” presented by Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology, Emory University School of Medicine, Atlanta, GA
- Scientific Platform Session III, Red Rock Ballroom
- Tuesday, March 19, 10:30 am – 10:45 am PDT